Back to News
News

Nobel Prize in Medicine Awarded for Advancements in Optogenetics

The 2026 Nobel Prize in Medicine recognizes Karl Deisseroth, Peter Hegemann, and Georg Nagel for their pioneering work in optogenetics.

Mercation Admin
October 5, 2026 2 min read
Nobel Prize in Medicine Awarded for Advancements in Optogenetics

The Nobel Assembly at the Karolinska Institute has awarded the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their groundbreaking work in optogenetics, a technique that activates nerve cells using light.

This prestigious award includes a prize of 12 million Swedish kronor (around $1.2 million), which will be evenly distributed among the three laureates.

According to the Nobel Committee, "Hegemann and Nagel discovered an extraordinary protein — channelrhodopsin — in single-celled algae, while Deisseroth transformed this protein into a light-controlled switch for nerve cells. Their contributions mark the dawn of a new era in neurobiology."

Optogenetics holds significant potential for understanding how specific neurons influence memory, emotions, and behavior.

Understanding Optogenetics

The origins of optogenetics trace back to the Chlamydomonas algae, which can navigate towards light. Researchers in the 20th century identified connections between brain regions and their functions but struggled to pinpoint the nerve cells responsible for specific actions or feelings.

Nobel laureate Francis Crick suggested utilizing light to manipulate neurons, as traditional methods could not keep pace with the rapid development of nerve signals.

In the early 1990s, Hegemann studied how Chlamydomonas detects light through a light-sensitive structure. He found that the electrical response occurred within 0.5 milliseconds of light exposure, significantly faster than human vision.

Hegemann theorized that a single protein could both detect light and act as an ion channel, a controversial idea at the time. Teaming up with Nagel, who used frog eggs to study proteins, they introduced Chlamydomonas genes into the cells, leading to the discovery of channelrhodopsin-1 and channelrhodopsin-2, which could open in response to light.

In 2003, their findings demonstrated that channelrhodopsin-2 could generate electrical signals in cells when exposed to light.

Deisseroth later took their discovery further, seeking to selectively activate neurons to investigate mental disorders. He introduced the channelrhodopsin-2 gene into rat neurons, which began to generate nerve signals when exposed to blue light.

This pivotal work was recognized by the Nobel Committee in 2005, establishing channelrhodopsin as a crucial tool for manipulating nerve cells.

By 2007, Deisseroth had successfully introduced the gene into motor cortex neurons of live mice, controlling their whisker movements through implanted optical fibers. This year also saw experiments demonstrating light activation of neurons linked to wakefulness, effectively waking sleeping mice, showcasing optogenetics' potential for controlling neural circuits in living brains.

In 2012, Deisseroth and Susumu Tonegawa activated a memory trace in mice, triggering a fear response without an actual threat, allowing researchers to map circuits involved in various behaviors and mental health conditions.

Future Prospects

Optogenetics is currently being explored in clinical settings, particularly for restoring vision in patients with retinitis pigmentosa. Promising results have emerged from clinical trials aimed at helping these individuals regain sight.

Future applications could also enhance cochlear implants. Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine, emphasized that optogenetics has unlocked new avenues for mapping the brain that were once considered unattainable.

Additionally, it is notable that the Turing Award for 2025 was recently awarded for advancements in quantum informatics to Gilles Brassard and Charles Bennett.